EverSource Wealth Advisors LLC Increases Holdings in Solventum Co. (NYSE:SOLV)

EverSource Wealth Advisors LLC lifted its position in shares of Solventum Co. (NYSE:SOLV) by 48.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 687 shares of the company’s stock after acquiring an additional 223 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Solventum were worth $45,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Sequoia Financial Advisors LLC boosted its stake in shares of Solventum by 27.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 7,317 shares of the company’s stock worth $483,000 after acquiring an additional 1,580 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in Solventum by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 18,871 shares of the company’s stock valued at $1,247,000 after buying an additional 1,248 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Solventum by 6.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 111,757 shares of the company’s stock valued at $7,383,000 after buying an additional 6,841 shares in the last quarter. Mayar Capital Ltd. lifted its stake in Solventum by 187.1% in the 4th quarter. Mayar Capital Ltd. now owns 30,290 shares of the company’s stock valued at $2,001,000 after buying an additional 19,739 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in Solventum in the 4th quarter valued at approximately $337,000.

Analyst Ratings Changes

SOLV has been the topic of a number of recent research reports. Mizuho upped their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Bank of America boosted their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Morgan Stanley boosted their price target on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. Finally, Wells Fargo & Company boosted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.86.

Solventum Trading Up 1.4 %

SOLV stock opened at $76.36 on Thursday. The company has a market cap of $13.21 billion and a price-to-earnings ratio of 27.77. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business has a fifty day simple moving average of $74.92 and a 200-day simple moving average of $71.42. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.